Outcome Measures in Cutaneous Autoimmune Disease: Dermatomyositis and Lupus Erythematosus

Handbook of Systemic Autoimmune Diseases

Volumn 5, Issue , 2006, Pages 207-220

  Albrecht, Joerg ^a   Werth, Victoria P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249308752     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(05)05015-4     Document Type: Review

References (51)

1. Albrecht J., Taylor L., Berlin J., et al. The CLASI (Cutaneous LE Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. J. Invest Dermatol. 125 (2005) 889
2. Anon. 1993. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology 186, 23.
3. Anon. 2003, Concept Paper Systemic Lupus Erythematosus.
4. Berth-Jones J., Thompson J., and Graham-Brown R.A. Evening primrose oil and atopic eczema. Lancet 345 (1995) 520
5. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (first of two parts). New Engl. J. Med. 292 (1975) 344
6. Bombardier C., Gladman D.D., and Urowitz M.B.etal. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 35 (1992) 630
7. Carr A.J., and Higginson I.J. Are quality of life measures patient centred?. BMJ 322 (2001) 1357
8. Carrol, C.L., Lang, W., Snively, B. et al. Development and Validation of the Dermatomyositis Skin Severity Index (DSSI). In press.
9. Charman C., and Williams H. Outcome measures of disease severity in atopic eczema. Arch. Dermatol. 136 (2000) 763
10. Charman C.R., Venn A.J., and Williams H.C. Measurement of body surface area involvement in atopic eczema: an impossible task? Br. J. Dermatol. 140 (1999) 109
11. Cohen J.B. Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int. J. Dermatol. 41 (2002) 182
12. el Azhary R.A., and Pakzad S.Y. Amyopathic dermatomyositis: retrospective review of 37 cases. J. Am. Acad. Dermatol. 46 (2002) 560
13. Euwer R.L., and Sontheimer R.D. Amyopathic dermatomyositis:a review. J. Invest Dermatol. 100 (1993) 124S
14. Farrar J.T., Berlin J.A., and Strom B.L. Clinically important changes in acute pain outcome measures: a validation study. J. Pain Symptom Manage. 25 (2003) 406
15. Faust H.B., Gonin R., Chuang T.Y., et al. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch. Dermatol. 133 (1997) 1443
16. Finlay A.Y. Measurement of disease activity and outcome in atopic dermatitis. Br. J. Dermatol. 135 (1996) 509
17. Gladman D.D., Urowitz M.B., Ong A., et al. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 5 (1996) 190
18. Hanly J.G. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study. Lupus 6 (1997) 243
19. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. 86 (1993) 447
20. Hochbert M.C., Engel E.W., Pruitt A., et al. Correlations of disease activity with physical disability in SLE. Arthritis Rheum. 222 (1990) S33
21. Isenberg D.A., Allen E., Farewell V., et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43 (2004) 49
22. Krueger G., Koo J., Lebwohl M., et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137 (2001) 280
23. Kunz B., Oranje A.P., Labreze L., et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 195 (1997) 10
24. Lahti A., Kopola H., Harila A., et al. Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chromameter. Arch. Dermatol. Res. 285 (1993) 278
25. Liang M.H., Socher S.A., Larson M.G., et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32 (1989) 1107
26. Long C.C., Mills C.M., and Finlay A.Y. A practical guide to topical therapy in children. Br. J. Dermatol. 138 (1998) 293
27. Lovell D.J., Lindsley C.B., Rennebohm R.M., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 42 (1999) 2213
28. Lucky A.W., Barber B.L., Girman C.J., et al. A multirater validation study to assess the reliability of acne lesion counting. J. Am. Acad. Dermatol. 35 (1996) 559
29. Miller F.W., Rider L.G., Chung Y.L., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 (2001) 1262
30. Miller S.F., Finley R.K., Waltman M., et al. Burn size estimate reliability: a study. J. Burn Care Rehabil. 12 (1991) 546
31. Nichol M.B., Margolies J.E., Lippa E., et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 10 (1996) 644
32. O'Quinn S.E., Cole J., and Many H. Problems of disability and rehabilitation in patients with chronic skin diseases. Arch. Dermatol. 105 (1972) 35
33. Oranje A.P., Stalder J.F., Taieb A., et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr. Allergy Immunol. 8 (1997) 28
34. Parodi A., Massone C., Cacciapuoti M., et al. Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br. J. Dermatol. 142 (2000) 457
35. Quinn A.G., McLelland J., Essex T., et al. Quantification of contact allergic inflammation: a comparison of existing methods with a scanning laser Doppler velocimeter. Acta Derm.Venereol. 73 (1993) 21
36. Ramsay B., and Lawrence C.M. Measurement of involved surface area in patients with psoriasis. Br. J. Dermatol. 124 (1991) 565
37. Rider L., Lachenbruch P.A., Rennebohm R.M., et al. Identifying skin lesions in dermatomyositis (DM): Inter-rater reliability of a new cutaneous assessment tool (CAT). Arthritis. Rheum. 38 Suppl. (1995) S168
38. Rider L.G., Feldman B.M., Perez M.D., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 40 (1997) 1976
39. Rider L.G., Giannini E.H., Brunner H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 50 (2004) 2281
40. Sontheimer R.D. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr. Opin. Rheumatol. 11 (1999) 475
41. Sontheimer R.D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J. Am. Acad. Dermatol. 46 (2002) 626
42. Sontheimer, R.D., Provost, T.T. 2003. In: R.L. Euwer, R.D. Sontheimer (Eds.), Cutaneous Manifestation of Rheumatic Diseases. Lippincott Williams & Wilkins, Philadelphia.
43. Streiner D.L., and Norman G.R. Health Measurement Scales (1995), a Practical Guide to their Development and Use. Oxford University Press, Oxford
44. Tebbe B., and Orfanos C.E. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 6 (1997) 96
45. Tiling-Grosse S., and Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br. J. Dermatol. 128 (1993) 69
46. Urowitz M.B., Gladman D.D., Tozman E.C., et al. The lupus activity criteria count (LACC). J. Rheumatol. 11 (1984) 783
47. Vardy D., Besser A., Amir M., et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br. J. Dermatol. 147 (2002) 736
48. Vlachoyiannopoulos P.G., Karassa F.B., Karakostas K.X., et al. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 2 (1993) 303
49. Whiting-O'Keefe Q.E., Stone J.H., and Hellmann D.B. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum. 42 (1999) 2365
50. Williams H. "Objective" measures of atopic dermatitis severity: in search of the holy Grail. Arch. Dermatol. 139 (2003) 1490
51. Williams H.C. Is a simple generic index of dermatologic disease severity an attainable goal? Arch. Dermatol. 133 (1997) 1451